A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies

Rangaramanujam M Kannan¹, Ian Pitha², Kunal S Parikh³

Affiliations

¹ Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Departments of Chemical and Biomolecular Engineering and Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA. Electronic address: krangar1@jhmi.edu.
² Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Bioengineering Innovation & Design, Johns Hopkins University, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 37419213
DOI: 10.1016/j.addr.2023.115005

Review

A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies

Rangaramanujam M Kannan et al. Adv Drug Deliv Rev. 2023 Sep.

. 2023 Sep:200:115005.

doi: 10.1016/j.addr.2023.115005. Epub 2023 Jul 6.

Authors

Rangaramanujam M Kannan¹, Ian Pitha², Kunal S Parikh³

Affiliations

¹ Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Departments of Chemical and Biomolecular Engineering and Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA. Electronic address: krangar1@jhmi.edu.
² Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Bioengineering Innovation & Design, Johns Hopkins University, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 37419213
DOI: 10.1016/j.addr.2023.115005

Abstract

Vision impairment and loss due to posterior segment ocular disorders, including age-related macular degeneration and diabetic retinopathy, are a rapidly growing cause of disability globally. Current treatments consist primarily of intravitreal injections aimed at preventing disease progression and characterized by high cost and repeated clinic visits. Nanotechnology provides a promising platform for drug delivery to the eye, with potential to overcome anatomical and physiological barriers to provide safe, effective, and sustained treatment modalities. However, there are few nanomedicines approved for posterior segment disorders, and fewer that target specific cells or that are compatible with systemic administration. Targeting cell types that mediate these disorders via systemic administration may unlock transformative opportunities for nanomedicine and significantly improve patient access, acceptability, and outcomes. We highlight the development of hydroxyl polyamidoamine dendrimer-based therapeutics that demonstrate ligand-free cell targeting via systemic administration and are under clinical investigation for treatment of wet age-related macular degeneration.

Keywords: Age-related macular degeneration; Clinical trial; Dendrimer; Diabetic retinopathy; Drug delivery; Eye; Glaucoma; Nanomedicine; Sustained release.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest IP and KSP declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this publication. RMK is a co-founder and former board member of Ashvattha Therapeutics, Inc. Under license agreements involving Ashvattha Therapeutics, Inc and the Johns Hopkins University, RMK and Johns Hopkins University are entitled to royalty distributions related to products discussed in this manuscript. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. RMK is an inventor of patents licensed by Ashvattha, relating to the hydroxyl dendrimer-drug compositions.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies

Affiliations

A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical